Phosphorylated Tau and Amyloid‑Beta Detected Early via Simple Blood Test

A breakthrough study featured in The Lancet reports that two hallmark proteins of Alzheimer’s disease—phosphorylated tau (p‑tau) and amyloid‑beta (Aβ)—can be reliably measured in the bloodstream of individuals who are still in the middle‑age bracket. The researchers recruited participants without overt dementia and quantified p‑tau and Aβ using ultra‑sensitive assay techniques. A proportion of the sample exhibited abnormal biomarker patterns, and these individuals consistently scored lower on memory recall and executive function exams. Adjustments for age, body‑mass index, kidney filtration rate and APOE genotype did not diminish the strength of these findings. Sub‑analyses hinted at variations across sex, race and genetic risk, with Black participants, females and those carrying the APOE4 allele showing the most robust associations. While the test is far from a definitive diagnostic tool, the authors propose that it could become an affordable screening method to identify people who might benefit from preventative strategies.